Pharma Journalist -

Seagen Inc. and LAVA Therapeutics N.V. announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced…
Read More...

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA (brincidofovir), the first oral antiviral approved by the U.S. Food…
Read More...

SAE Media Group reports: Conference co-chairs invite you to attend the 2nd Annual Next Generation Pharmaceutical Cleanrooms this October 2022. The conference will be co-chaired…
Read More...

AstraZeneca and MSD’s Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary…
Read More...

Massive Bio, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial…
Read More...

Merck, known as MSD outside of the United States and Canada, announced that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent…
Read More...

Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are…
Read More...

GSK plc and Spero Therapeutics, Inc. announced they have entered into an exclusive licence agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic being…
Read More...

Pfizer Inc. announced an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID (nirmatrelvir tablets and ritonavir tablets) to Global Fund as…
Read More...

Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), announced an exclusive collaboration…
Read More...